Close

Instinet Reiterates Buy Rating and $148 PT on Alexion Pharma (ALXN) Following Meetings with CEO & CFO

March 30, 2017 8:22 AM EDT Send to a Friend
Instinet reiterates Buy rating and $148 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following meetings with new CEO ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login